Simon Collins blog

Bite-size news from EACS 2015… remarkable results with dolutegravir monotherapy

NOTE: AT CROI 2017, A HIGHER RISK OF VIRAL REBOUND AND DEVELOPMENT OF INTEGRASE INHIBITOR DRUG RESISTANCE MEANS THAT DOLUTEGRAVIR MONOTHERAPY IS NOT RECOMMENDED. ANYONE USING DOLUTEGRAVIR IS RECOMMENDED TO SWITCH TO DUAL OR TRIPLE THERAPY.  http://i-base.info/htb/31289 …………………………………….. Simon Collins, HIV i-Base …